Literature DB >> 10199307

Familial patterns of thoracic aortic aneurysms.

M A Coady1, R R Davies, M Roberts, L J Goldstein, M J Rogalski, J A Rizzo, G L Hammond, G S Kopf, J A Elefteriades.   

Abstract

HYPOTHESIS: To provide evidence that genetic factors contribute to the development of thoracic aortic aneurysms (TAA) by demonstrating familial patterns of the disease.
DESIGN: Retrospective review.
SETTING: University hospital. PATIENTS AND METHODS: We sought to identify familial patterns of TAA from a database of 598 patients evaluated or treated for TAA at the Yale Center for Thoracic Aortic Disease, New Haven, Conn, from January 1985 to August 1998. Of the 598 patients, 45 patients had a diagnosis of Marfan syndrome and 553 patients had no known history of any collagen vascular disorder. Of the 553 patients in the latter category, 398 patients had confirmed TAA, 66 had TAA with concomitant aortic dissections, and 89 had aortic dissections. From the group of 464 patients with TAA with or without concomitant aortic dissections, 2 interviewers attempted to contact 150 randomly selected patients for telephone screening to determine the presence of familial patterns of aortic disease. Fifteen of these patients were lost to follow-up. Complete medical and family histories of the remaining 135 patients (85 men, 50 women) were reviewed. Of the 135 individuals screened, 26 (18 men, 8 women) (19.3%) were found to belong to multiplex pedigrees. These 26 patients with familial nonsyndromic TAA were compared with the remaining 109 patients with sporadic TAA and the 45 patients with Marfan syndrome-associated TAA. MAIN OUTCOME MEASURES: Groups were examined for statistical differences in age and aortic size at the time of diagnosis, growth rates of TAA, and rates of concomitant diseases. Nonsyndromic family pedigrees were analyzed and potential modes of inheritance were determined.
RESULTS: The mean age at presentation for patients with familial nonsyndromic TAA (56.8 years) was significantly younger than the mean age of presentation in sporadic cases (64.3 years, P< or =.03), and significantly older than that of patients with Marfan syndrome (24.8 years, P< or =.001). Patients with a family history of aortic aneurysms had faster growth rates (0.22 cm/y) compared with patients with sporadic TAA (0.03 cm/y) (P< or =.001) and patients with Marfan syndrome (0.10 cm/y) (P< or =.04). Familial nonsyndromic TAA in patients with a concomitant aortic dissection had a growth rate of 0.33 cm/y, which was greater than that of patients with sporadic TAA (0.10 cm/y) and patients with Marfan syndrome (0.08 cm/y) with associated aortic dissection. This growth of 0.33 cm/y was significantly faster than the overall growth rate estimate of aneurysms in patients with aortic dissection (0.14 cm/y) (P< or =.05). Ten pedigrees (38.5%) showed direct father to son transmission, consistent with an autosomal dominant mode of inheritance. Six family pedigrees (23.1%) suggested an autosomal dominant or X-linked mode of inheritance. Seven pedigrees (26.9%) suggested a recessive mode of inheritance; 2 an autosomal recessive mode, and 5 an X-linked recessive or autosomal recessive mode. The remaining 3 pedigrees displayed more complex modes of inheritance.
CONCLUSIONS: This study supports the role of genetic factors influencing familial aggregation of TAA. Thoracic aortic aneurysms in association with multiplex pedigrees represent a new risk factor for aneurysm growth. Pedigree analysis suggests genetic heterogeneity. The primary mode of inheritance seems to be autosomal dominant, but X-linked dominant and recessive modes are also evident.

Entities:  

Mesh:

Year:  1999        PMID: 10199307     DOI: 10.1001/archsurg.134.4.361

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  72 in total

Review 1.  Genetic testing in aortic aneurysm disease: PRO.

Authors:  Dianna M Milewicz; Alicia A Carlson; Ellen S Regalado
Journal:  Cardiol Clin       Date:  2010-05       Impact factor: 2.213

2.  Points to consider: genetic evaluation of the cardiology patient.

Authors:  Heather MacLeod
Journal:  J Cardiovasc Transl Res       Date:  2009-06-10       Impact factor: 4.132

3.  Aortic dimensions and the risk of dissection.

Authors:  Raimund Erbel; Holger Eggebrecht
Journal:  Heart       Date:  2006-01       Impact factor: 5.994

4.  Genes in thoracic aortic aneurysms/dissections - do they matter?

Authors:  Julie De Backer; Laurence Campens; Anne De Paepe
Journal:  Ann Cardiothorac Surg       Date:  2013-01

Review 5.  Aetiology and management of hereditary aortopathy.

Authors:  Aline Verstraeten; Ilse Luyckx; Bart Loeys
Journal:  Nat Rev Cardiol       Date:  2017-01-19       Impact factor: 32.419

6.  Postmortem genetic testing should be recommended in sudden cardiac death cases due to thoracic aortic dissection.

Authors:  Marina Gago-Díaz; Eva Ramos-Luis; Silvia Zoppis; Esther Zorio; Pilar Molina; Aitana Braza-Boïls; Juan Giner; Beatriz Sobrino; Jorge Amigo; Alejandro Blanco-Verea; Ángel Carracedo; María Brion
Journal:  Int J Legal Med       Date:  2017-04-08       Impact factor: 2.686

Review 7.  Genes Associated with Thoracic Aortic Aneurysm and Dissection: An Update and Clinical Implications.

Authors:  Adam J Brownstein; Bulat A Ziganshin; Helena Kuivaniemi; Simon C Body; Allen E Bale; John A Elefteriades
Journal:  Aorta (Stamford)       Date:  2017-02-01

Review 8.  Open Versus Endovascular or Hybrid Thoracic Aortic Aneurysm Repair.

Authors:  Ryan Clare; Julianne Jorgensen; Somjot S Brar
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

9.  TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction.

Authors:  Katharine J Bee; David C Wilkes; Richard B Devereux; Craig T Basson; Cathy J Hatcher
Journal:  Circ Cardiovasc Genet       Date:  2012-10-24

10.  Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC).

Authors:  Kim A Eagle
Journal:  Am Heart J       Date:  2008-12-17       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.